Eli Lilly's GLP-1 Drugs Ignite Growth episode artwork

EPISODE · May 4, 2026 · 1 MIN

Eli Lilly's GLP-1 Drugs Ignite Growth

from The Daily News Now! Business

Eli Lillys Q1 2026 earnings surged 56% to $19.8 billion, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound, which raked in $12.8 billion. Mounjaros sales are balanced between U.S. and international markets, while Zepbound, a weight loss champ, is primarily domestic. Despite a 10% share drop and high valuation, investors are optimistic about long-term wins, especially with recent approvals and promising trials for new drugs. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fa88aa05b1ad0e85

NOW PLAYING

Eli Lilly's GLP-1 Drugs Ignite Growth

0:00 1:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Daily News Now! Business?

This episode is 1 minute long.

When was this The Daily News Now! Business episode published?

This episode was published on May 4, 2026.

What is this episode about?

Eli Lillys Q1 2026 earnings surged 56% to $19.8 billion, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound, which raked in $12.8 billion. Mounjaros sales are balanced between U.S. and international markets, while Zepbound, a weight loss...

Can I download this The Daily News Now! Business episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!